Ultragenyx Pharmaceutical Inc.
RARE | NASDAQ
$15.79
+$1.14 (+7.78%)
Sep 22, 2026, 1:23 PM ET · Market open
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 30, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 214M | 136M | 207M | 159.93M | 166.5M | 139.29M | 164.88M | 139.49M | 147.03M | 108.83M | 127.39M | 98.05M | 108.31M | 100.5M | 103.35M | 90.7M | 89.34M | 79.94M | 83.39M | 81.65M | 86.98M | 99.4M |
Cost of Revenue | 34M | 30M | 29M | 27.99M | 23M | 28.66M | 16.89M | 21.02M | 21.28M | 17.53M | 12.05M | 10.99M | 9.91M | 12.26M | 5.32M | 8.63M | 8.27M | 6.1M | 3.51M | 4.18M | 3.14M | 5.19M |
Gross Profit | 180M | 106M | 178M | 131.94M | 143.49M | 110.63M | 147.98M | 118.47M | 125.75M | 91.3M | 115.34M | 87.07M | 98.4M | 88.24M | 98.03M | 82.07M | 81.07M | 73.84M | 79.88M | 77.47M | 83.84M | 94.21M |
Operating Income | -75M | -169M | -114M | -170.89M | -107.89M | -142.94M | -122.28M | -131.99M | -116.36M | -165.35M | -122.05M | -145.1M | -147.96M | -154.11M | -145.63M | -225.07M | -141.59M | -136.63M | -102.56M | -89.83M | -82.78M | -106.57M |
Interest Income | 5M | 6M | 6.51M | 5.86M | 5.79M | 6.83M | 9.55M | 10.73M | 7.4M | 8.82M | 8.55M | 5.88M | 5.96M | 6.29M | 6.2M | 3.48M | 899K | 494K | 440K | 408K | 441K | 639K |
Pretax Income | -91M | -184M | -128M | -179.54M | -114M | -149.77M | -133.4M | -133.21M | -130.74M | -170.23M | -126.89M | -159M | -159.1M | -163.48M | -153.28M | -238.82M | -157.86M | -151.76M | -122.44M | -72.82M | -121.97M | -135.76M |
Net Income | -92M | -185M | -129M | -180.41M | -114.95M | -151.08M | -133.39M | -133.52M | -131.6M | -170.68M | -123.19M | -159.65M | -159.83M | -163.97M | -151.83M | -245.11M | -158.16M | -152.32M | -122.46M | -73M | -122.43M | -136.14M |
Selling & General & Admin | 88M | 88M | 89M | 86.62M | 86.65M | 87.8M | 82.5M | 80.35M | 80.6M | 78.16M | 76.83M | 74.92M | 81.4M | 76.65M | 72.85M | 69.84M | 68.14M | 67.31M | 59.43M | 53.88M | 53.41M | 53.26M |
Research & Development | 167M | 187M | 203M | 216.21M | 164.74M | 165.77M | 187.77M | 170.11M | 161.5M | 178.49M | 160.56M | 157.25M | 164.95M | 165.7M | 170.81M | 237.3M | 154.53M | 143.16M | 123.01M | 113.42M | 113.21M | 147.52M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 255M | 275M | 292M | 302.83M | 251.38M | 253.57M | 270.26M | 250.46M | 242.11M | 256.65M | 237.39M | 232.16M | 246.35M | 242.34M | 243.66M | 307.14M | 222.67M | 210.47M | 182.44M | 167.3M | 166.62M | 200.78M |
Interest Expense | 22M | 21M | 19M | 14.15M | 14.04M | 14.34M | 15.52M | 15.71M | 15.96M | 15.85M | 17.33M | 17.67M | 15.38M | 15.64M | 15.87M | 14.51M | 6.05M | 6.58M | 3.8M | 8.68M | 8.52M | 8.42M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 289M | 305M | 321M | 330.82M | 274.38M | 282.23M | 287.16M | 271.48M | 263.39M | 274.18M | 249.44M | 243.15M | 256.27M | 254.6M | 248.98M | 315.77M | 230.94M | 216.57M | 185.95M | 171.48M | 169.75M | 205.96M |
Income Tax Expense | 1M | 1M | 1M | 873K | 947K | 1.31M | -19K | 303K | 858K | 455K | -3.7M | 650K | 732K | 495K | -1.45M | 6.29M | 302K | 558K | 20K | 182K | 463K | 379K |
Shares Outstanding (Basic) | 101.9M | 100.6M | 99.9M | 99.77M | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M | 81.12M | 71.66M | 70.9M | 70.37M | 70.15M | 70.05M | 69.93M | 69.52M | 68.57M | 67.88M | 67.61M | 67.1M |
Shares Outstanding (Diluted) | 101.9M | 100.6M | 99.9M | 99.77M | 98.46M | 96.29M | 95.68M | 95.49M | 86.58M | 84.29M | 81.12M | 71.66M | 70.9M | 70.37M | 70.15M | 70.05M | 69.93M | 69.52M | 68.57M | 67.88M | 67.61M | 67.1M |
EPS (Basic) | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 | -2.33 | -2.16 | -3.50 | -2.26 | -2.19 | -1.79 | -1.08 | -1.81 | -2.03 |
EPS (Diluted) | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 | -1.39 | -1.40 | -1.52 | -2.03 | -1.52 | -2.23 | -2.25 | -2.33 | -2.16 | -3.50 | -2.26 | -2.19 | -1.79 | -1.08 | -1.81 | -2.03 |
EBITDA | -61M | -155M | -100.22M | -156.79M | -91.34M | -126.44M | -108.8M | -108.74M | -105.92M | -145.54M | -101.35M | -134.14M | -138.36M | -142.61M | -132.45M | -219.62M | -147.33M | -141.09M | -115.1M | -60.92M | -110.33M | -123.98M |
EBIT | -69M | -163M | -109M | -165.39M | -99.96M | -135.43M | -117.88M | -117.5M | -114.78M | -154.38M | -109.56M | -141.33M | -143.72M | -147.84M | -137.41M | -224.31M | -151.81M | -145.18M | -118.63M | -64.13M | -113.45M | -127.34M |
Depreciation & Amortization | 8M | 8M | 8.79M | 8.61M | 8.62M | 8.99M | 9.08M | 8.76M | 8.86M | 8.85M | 8.22M | 7.19M | 5.36M | 5.24M | 4.96M | 4.69M | 4.48M | 4.09M | 3.53M | 3.22M | 3.12M | 3.37M |
Add to Watchlist
Select watchlists to add or remove RARE